Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Molecularly targeted therapies have advanced cancer treatment, improving patient survival over conventional chemotherapy.
• These novel therapies can cause a range of kidney adverse events due to off-target effects.
• Understanding and managing these nephrotoxicities is vital for sustained therapeutic use.

Purpose of the Study:

• To review the mechanisms of action of novel targeted therapies.
• To describe the clinical findings associated with kidney adverse events.
• To outline proposed management strategies for drug-induced kidney toxicities.

Main Methods:

• Literature review of molecularly targeted therapies and their associated nephrotoxicities.
• Analysis of mechanisms of action, clinical presentations, and management approaches.
• Synthesis of current knowledge on kidney adverse events from targeted agents.

Main Results:

• Targeted therapies, despite their name, often lack specificity, leading to kidney damage.
• Nephrotoxicity patterns vary based on the drug's specific molecular target.
• Effective management strategies are essential for continuing potent cancer treatments.

Conclusions:

• Kidney adverse events are a significant concern with novel targeted therapies.
• Prompt identification and management of nephrotoxicity are key to preserving renal function.
• Further research into targeted therapy-induced kidney toxicities is warranted.